jazz pharmaceuticals plc merger jazz pharmaceuticals inc azur pharma plc biopharmaceutical company based ireland founded one companys considerable products united states food drug administration fda approved drug xyrem sodium oxybate sodium salt naturally occurring neurotransmitter γhydroxybutyric acid ghb net product sales xyrem billion represented companys total net product jazz granted fdaapproval market sunosi indications treating excessive daytime sleepiness eds narcolepsy well obstructive sleep apnea osa announced axsome therapeutics would acquiring sunosi jazz company pled guilty felony charges related illegal marketing xyrem offlabel company also member pharmaceutical research manufacturers america february fda accepted new drug application sodium oxybate treatment following december new patent issued sodium september jazz pharmaceuticals merged irish azur pharma plc form jazz pharmaceuticals plc azur pharma seat dublin became headquarters combined company azur pharma marketing specialty pharmaceutical products central nervous system cns womens health areas us operations april company acquired eusa pharma million plus million milestone september company sold womens health business meda december company began clinical trial intravenous erwinaze patients acute lymphoblastic january company announced would acquire rare disease drug developer gentium spa lead product defitelio may company announced would acquire alizé pharma ii end month company announced largest acquisition date purchase celator pharmaceuticals result jazz obtained rights breakthrough therapy vyxeos liposomal daunorubicin cytarabine treatment acute myeloid august company announced would acquire cavion inc january jazz announced would acquire gw pharmaceuticals billion usd usd per adr cash shares following illustration companys mergers acquisitions spinoffs historical predecessors httpsenwikipediaorgwikijazzpharmaceuticals